Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy. Here, nonhuman primates (NHPs) received either no vaccine or doses ranging from 0.3 to 100 mg of the mRNA-1273 severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2) vaccine. mRNA-1273 vaccination elicite...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Science (American Association for the Advancement of Science) 2021-09, Vol.373 (6561), p.1325-eabj0299
Hauptverfasser:	Corbett, Kizzmekia S., Nason, Martha C., Flach, Britta, Gagne, Matthew, O' Connell, Sarah, Johnston, Timothy S., Shah, Shruti N., Edara, Venkata Viswanadh, Floyd, Katharine, Lai, Lilin, McDanal, Charlene, Francica, Joseph R., Flynn, Barbara, Wu, Kai, Choi, Angela, Koch, Matthew, Abiona, Olubukola M., Werner, Anne P., Moliva, Juan, Andrew, Shayne F., Donaldson, Mitzi M., Fintzi, Jonathan, Flebbe, Dillon R., Lamb, Evan, Noe, Amy T., Nurmukhambetova, Saule T., Provost, Samantha J., Cook, Anthony, Dodson, Alan, Faudree, Andrew, Greenhouse, Jack, Kar, Swagata, Pessaint, Laurent, Porto, Maciel, Steingrebe, Katelyn, Valentin, Daniel, Zouantcha, Serge, Bock, Kevin W., Minai, Mahnaz, Nagata, Bianca M., van de Wetering, Renee, Boyoglu-Barnum, Seyhan, Leung, Kwanyee, Shi, Wei, Yang, Eun Sung, Zhang, Yi, Todd, John-Paul M., Wang, Lingshu, Alvarado, Gabriela S., Andersen, Hanne, Foulds, Kathryn E., Edwards, Darin K., Mascola, John R., Moore, Ian N., Lewis, Mark G., Carfi, Andrea, Monterfiori, David, Suthar, Mehul S., McDermott, Adrian, Roederer, Mario, Sullivan, Nancy J., Douek, Daniel C., Graham, Barney S., Seder, Robert A.
Format:	Artikel
Sprache:	eng
Schlagworte:	2019-nCoV Vaccine mRNA-1273 Allergic diseases Alveoli Animals Antibodies Antibodies, Neutralizing - blood Antibodies, Neutralizing - immunology Antibodies, Viral - blood Antibodies, Viral - immunology Antibody Affinity Antigens Bronchoalveolar Lavage Fluid - immunology Bronchoalveolar Lavage Fluid - virology Bronchus CD4-Positive T-Lymphocytes - immunology Cell-mediated immunity Clinical trials Combined vaccines Coronaviruses COVID-19 COVID-19 - immunology COVID-19 - prevention & control COVID-19 - virology COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - immunology Disease transmission Female Glycoprotein S Glycoproteins Hamsters Health promotion Humoral immunity IgG antibody Immune response (humoral) Immunity Immunization Immunization Schedule Immunization, Passive Immunization, Secondary Immunogenicity Immunogenicity, Vaccine Immunoglobulin G Immunoglobulin G - immunology Immunoglobulins Immunologic Memory Infections Inflammation Innate immunity Lavage Lung - immunology Lung - virology Lungs Lymphocytes Lymphocytes T Macaca mulatta Male Mesocricetus mRNA Mucosa Multidisciplinary Sciences Nasal Mucosa - immunology Nasal Mucosa - virology Pandemics Primates Public health Reduction Replication Respiratory diseases Respiratory tract Respiratory tract diseases SARS-CoV-2 - immunology SARS-CoV-2 - physiology Science & Technology Science & Technology - Other Topics Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Spike Glycoprotein, Coronavirus - immunology Spike protein Vaccination Vaccine efficacy Vaccine Potency Vaccines Viral diseases Virus Replication
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy. Here, nonhuman primates (NHPs) received either no vaccine or doses ranging from 0.3 to 100 mg of the mRNA-1273 severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2) vaccine. mRNA-1273 vaccination elicited circulating and mucosal antibody responses in a dose-dependent manner. Viral replication was significantly reduced in bronchoalveolar lavages and nasal swabs after SARS-CoV-2 challenge in vaccinated animals and most strongly correlated with levels of anti-S antibody and neutralizing activity. Lower antibody levels were needed for reduction of viral replication in the lower airway than in the upper airway. Passive transfer of mRNA-1273-induced immunoglobulin G to naive hamsters was sufficient to mediate protection. Thus, mRNA-1273 vaccine-induced humoral immune responses are a mechanistic correlate of protection against SARS-CoV-2 in NHPs.
ISSN:	0036-8075 1095-9203
DOI:	10.1126/science.abj0299